Strong H1 2025 Performance
Sandoz delivered 4% sales growth, or 6% on an underlying basis. The core EBITDA margin expanded by 2.5 percentage points to reach 20%. Core diluted earnings per share grew by 33% at constant currency.
Successful Biosimilar Launches
Launched Pyzchiva in the U.S., and Pyzchiva auto-injector in Europe. Wyost and Jubbonti were launched in the U.S. as the first interchangeable denosumab biosimilars.
Pipeline and Manufacturing Expansion
Sandoz announced the expansion of its manufacturing capabilities in Slovenia and the planned acquisition of Just-Evotec Biologics' facilities in France.
Financial Flexibility Improved
Management free cash flow more than doubled to over $500 million, enhancing financial flexibility.
Strong Regional Growth
Europe sales grew by 6%, with strong contributions from biosimilars. International sales grew by an underlying 13% in Q2.